Wednesday October 9, 2019

1-5pm

San Francisco, CA

Transformational Next Generation Ocular Therapy

Inaugural Event

Register Now / Limited Space

Course Director

Kourous A Rezaei
Kourous A. Rezaei, MD

speakers

Christopher Brittain
Christopher Brittain
Global Head of Ophthalmology Clinical Development, Genentech
Division of Roche Holding
Adrienne Graves
Adrienne Graves, PhD
Former Chief Executive Officer
Santen
Daniel Chung
Daniel C. Chung, DO, MA
Global Medical Strategy Lead
Ophthalmology, Spark Therapeutics
Andreas Lauer
Andreas K. Lauer, MD
Chair, Department of Ophthalmology Casey Eye Institute
Oregon Health & Science University
Karl Csaky
Karl G. Csaky MD, PhD
T. Boone Pickens Director
Clinical Center of Innovation for AMD
Managing Director and Chief Medical Officer, Retina Foundation of the Southwest
Ken Mills
Ken Mills
President and Chief Executive Officer
REGENXBIO
Tuyen Ong
Tuyen Ong
Head of Ophthalmology Franchise
Biogen
Scott Dorfman
Scott Dorfman
Chief Executive Officer
Odylia Therapeutics
Leone Patterson
Leone Patterson
Chief Executive Officer
Adverum Biotechnologies
Jacque Duncan
Jacque L. Duncan, MD
Professor of Ophthalmology
University of California, San Francisco
Mark Pennesi
Mark Pennesi, MD, PhD
Division Chief, Ophthalmic Genetics Casey Eye Institute, Oregon Health and Science University
Guangping Gao
Guangping Gao, PhD
President, American Society of Gene & Cell Therapy, Director of Horae Gene Therapy Center, Director of Research Institute for Rare Diseases, Professor, Microbiology & Physiological Systems, University of Massachusetts Medical School
Christine Horama
Christine Placet
Chief Executive Officer
Horama
Susan Hill
Susan Hill
Chief Business Officer
Gyroscope Therapeutics
Mark Vezina
Scientific Director
Ocular and Neuroscience
Charles River Laboratories
Glenn P. Sblendorio
Glenn P. Sblendorio
Chief Executive Officer and President
IVERIC bio
Sue Washer
Sue Washer
Chief Executive Officer and President
Applied Genetic Technologies Corp.
Kali Stasi
Kali Stasi, MD, PhD
Translational Medicine Director
Novartis Institutes for BioMedical Research
Benjamin Yerxa
Benjamin Yerxa, PhD
Chief Executive Officer
Foundation Fighting Blindness
Pete Adamson
Vice President, Head, Retinal Disease Area Stronghold, Janssen
Alexandria Forbes, PhD
President and Chief Executive Officer, Meira GTx
Hannah Chang Wu
Hannah Chang, MD, PhD
Investment Director
Wu Capital USA
Gilbert H Kliman
Gilbert H. Kliman, MD
Managing Partner
InterWest Partners
Cyrus Mozayeni
Cyrus Mozayeni, MD
Co-founder & CEO
Vedere
Eugene de Juan
Eugene de Juan, MD
Founder & Managing Partner
ForSight Labs
Pravin Dugel, MD
Pravin Dugel, MD
Managing Partner / Clinical Professor
Retinal Consultants of Arizona; Retinal Research Institute / USC Roski Eye Institute Keck School of Medicine
K. Thiran Jayasundera, MD
K. Thiran Jayasundera, MD
Associate Professor, Ophthalmology and Visual Sciences,
Paul R. Lichter Professor of Ophthalmic Genetics
University of Michigan Kellogg Eye Center
Christine Nichols Kay, MD
Christine Nichols Kay, MD
Vitreo Retinal Associates
Gainesville, Florida
Magali Taiel
Magali Taiel, MD
Vice President of Clinical Development
Gensight Biologics
Hylton Kalvaria
Hylton Kalvaria
Vice President, Strategic Partnerships
Verana Health
Deborah Wild
Deborah Wild
Chief of Staff and VP of Corporate Development
Catalent Biologics, Paragon Gene Therapy
Register Now

Sponsors

Diamond
Platinum
Gold
Silver

Session I

12:30-12:59 Registration
13:00-13:02 Kourous A. Rezaei, MD Welcome
MODERATORS
Adrienne Graves, PhD
Former Chief Executive Officer of Santen
Kourous A. Rezaei, MD
13:03-13:08 Guangping Gao, PhD
President, American Society of Gene & Cell Therapy, Director of Horae Gene Therapy Center, Director of Research Institute for Rare Diseases, Professor, Microbiology & Physiological Systems, University of Massachusetts Medical School
AAV Gene Therapy for Eye Diseases
13:09-13:14 Daniel C. Chung, DO, MA
Global Medical Strategy Lead – Ophthalmology, Spark Therapeutic
Clinical Development of Voretigene Neparvovec-ryzl, a gene therapy for Biallelic RPE65 Mutation-associated Inherited Retinal Disease: An Update
13:15-13:20 Tuyen Ong
Head of Ophthalmology Franchise, Biogen
Biogen Pipeline Update
13:21-13:26 Sue Washer
President and Chief Executive Officer, Applied Genetic Technologies Corp.
AGTC Update on Clinical and Research Programs
13:27-13:32 Kali Stasi, MD, PhD
Translational Medicine Director, Novartis Institutes for BioMedical Research
Novartis Retinal Gene Therapy Update
13:33-13:40 Discussion
13:41-13:51 Panel
Pravin Dugel, MD; Hannah Chang, MD, PhD; Gilbert Kliman, MD; Eugene de Juan, MD

Session II

MODERATORS: Karl Csaky, MD, PhD and Kourous A. Rezaei, MD
13:52-13:57 Hylton Kalvaria
Vice President, Strategic Partnerships, Verana Health
Accelerating Inherited Disease Trials with Data Insights
13:58-14:03 Mark Pennesi, MD, PhD
Division Chief, Ophthalmic Genetics, Casey Eye Institute, Oregon Health & Science University
Gene Therapy in the Real World
14:04-14:09 Andreas K. Lauer, MD
Chair, Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University
Subretinal Surgery for Gene Therapy: Lessons Learned
14:10-14:15 Jacque L. Duncan, MD
Professor of Ophthalmology, University of California, San Francisco
Outcome Measures for Gene Therapy Clinical Trials
14:16-14:21 K. Thiran Jayasundera, MD
Associate Professor, Ophthalmology and Visual Sciences, Paul R. Lichter Professor of Ophthalmic Genetics
University of Michigan Kellogg Eye Center
Reported Patient Outcomes for Clinical Trials
14:22-14:27 Christine Nichols Kay, MD
Vitreo Retinal Associates, Gainesville, Florida
Genetic Testing: Real World Experience
14:28-14:33 Karl G. Csaky, MD, PhD
Gene Therapy: Lessons Learned & the Road Ahead
14:34-14:41 Discussion
14:42-14:52 Panel
Cyrus Mozayeni, MD; Karl Csaky, MD, PhD; Guangping Gao, PhD; Adrienne Graves, PhD

Session III

MODERATORS: Adrienne Graves, PhD and Kourous A. Rezaei, MD
14:53-14:58 Leone Patterson
Chief Executive Officer, Adverum Biotechnologies
ADVM-022, a Novel Gene Therapy in Development for Wet AMD
14:59-15:04 Glenn P. Sblendorio
Chief Executive Officer and President, IVERIC bio
IVERIC bio Gene Therapy Pipeline
15:05-15:10 Susan Hill
Chief Business Officer, Gyroscope Therapeutics
Gyroscope: Gene Therapy Beyond Rare Disease
15:11-15:16 Alexandria Forbes, PhD
President and Chief Executive Officer, Meira GTx
Meira GTx IRD Pipeline Update
15:17-15:22 Ken Mills
President and Chief Executive Officer, REGENXBIO
REGENXBIO: Driving Progress with Gene Therapy towards Transforming
15:23-15:28 Magali Taiel, MD
Vice President of Clinical Development, Gensight
GS010, a Novel Gene Therapy for Leber Hereditary Optic Neuropathy
15:29-15:34 Pete Adamson
Vice President, Head, Retinal Disease Area Stronghold, Janssen
Establishing Janssen’s Newest Leadership Area: Retinal Gene Therapy
15:35-15:42 Discussion

Session IV

MODERATORS: Eugene de Juan, MD and Kourous A. Rezaei, MD
15:43-15:48 Scott Dorfman
Chief Executive Officer, Odylia Therapeutics
Utilizing A Non-Profit Business Model for Ultra-Rare Indications
15:49-15:54 Christine Placet
Chief Executive Officer, Horama
Horama Pipeline Update
15:55-16:00 Christopher Brittain
Global Head of Ophthalmology Clinical Development, Genentech, Division of Roche Holding
Roche Gene Therapy Update
16:01-16:06 Benjamin Yerxa, PhD
Chief Executive Officer, Foundation Fighting Blindness
Role of FFB in Advancing Gene Therapy for Orphan Retinal Diseases
16:07-16:12 Mark Vezina
Scientific Director, Ocular and Neuroscience, Charles River Laboratories
Animal Models in Gene Therapy
16:13-16:18 Deborah Wild
Chief of Staff and VP of Corporate Development, Catalent Biologics, Paragon Gene Therapy
Challenges in Gene Therapy Manufacturing
16:19-16:26 Discussion
16:27-16:29 Kourous A. Rezaei, MD Final Remarks
16:30-17:00 Networking
Not a CME Event

Session I

12:30-12:59 Registration
13:00-13:02 Kourous A. Rezaei, MD Welcome
MODERATORS
Adrienne Graves, PhD
Former Chief Executive Officer of Santen
Kourous A. Rezaei, MD
13:03-13:08 Guangping Gao, PhD
President, American Society of Gene & Cell Therapy, Director of Horae Gene Therapy Center, Director of Research Institute for Rare Diseases, Professor, Microbiology & Physiological Systems, University of Massachusetts Medical School
AAV Gene Therapy for Eye Diseases
13:09-13:14 Daniel C. Chung, DO, MA
Global Medical Strategy Lead – Ophthalmology, Spark Therapeutic
Clinical Development of Voretigene Neparvovec-ryzl, a gene therapy for Biallelic RPE65 Mutation-associated Inherited Retinal Disease: An Update
13:15-13:20 Tuyen Ong
Head of Ophthalmology Franchise, Biogen
Biogen Pipeline Update
13:21-13:26 Sue Washer
President and Chief Executive Officer, Applied Genetic Technologies Corp.
AGTC Update on Clinical and Research Programs
13:27-13:32 Kali Stasi, MD, PhD
Translational Medicine Director, Novartis Institutes for BioMedical Research
Novartis Retinal Gene Therapy Update
13:33-13:40 Discussion
13:41-13:51 Panel
Pravin Dugel, MD; Hannah Chang, MD, PhD; Gilbert Kliman, MD; Eugene de Juan, MD

Session II

MODERATORS: Karl Csaky, MD, PhD and Kourous A. Rezaei, MD
13:52-13:57 Hylton Kalvaria
Vice President, Strategic Partnerships, Verana Health
Accelerating Inherited Disease Trials with Data Insights
13:58-14:03 Mark Pennesi, MD, PhD
Division Chief, Ophthalmic Genetics, Casey Eye Institute, Oregon Health & Science University
Gene Therapy in the Real World
14:04-14:09 Andreas K. Lauer, MD
Chair, Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University
Subretinal Surgery for Gene Therapy: Lessons Learned
14:10-14:15 Jacque L. Duncan, MD
Professor of Ophthalmology, University of California, San Francisco
Outcome Measures for Gene Therapy Clinical Trials
14:16-14:21 K. Thiran Jayasundera, MD
Associate Professor, Ophthalmology and Visual Sciences, Paul R. Lichter Professor of Ophthalmic Genetics
University of Michigan Kellogg Eye Center
Reported Patient Outcomes for Clinical Trials
14:22-14:27 Christine Nichols Kay, MD
Vitreo Retinal Associates, Gainesville, Florida
Genetic Testing: Real World Experience
14:28-14:33 Karl G. Csaky, MD, PhD
Gene Therapy: Lessons Learned & the Road Ahead
14:34-14:41 Discussion
14:42-14:52 Panel
Cyrus Mozayeni, MD; Karl Csaky, MD, PhD; Guangping Gao, PhD; Adrienne Graves, PhD

Session III

MODERATORS: Adrienne Graves, PhD and Kourous A. Rezaei, MD
14:53-14:58 Leone Patterson
Chief Executive Officer, Adverum Biotechnologies
ADVM-022, a Novel Gene Therapy in Development for Wet AMD
14:59-15:04 Glenn P. Sblendorio
Chief Executive Officer and President, IVERIC bio
IVERIC bio Gene Therapy Pipeline
15:05-15:10 Susan Hill
Chief Business Officer, Gyroscope Therapeutics
Gyroscope: Gene Therapy Beyond Rare Disease
15:11-15:16 Alexandria Forbes, PhD
President and Chief Executive Officer, Meira GTx
Meira GTx IRD Pipeline Update
15:17-15:22 Ken Mills
President and Chief Executive Officer, REGENXBIO
REGENXBIO: Driving Progress with Gene Therapy towards Transforming
15:23-15:28 Magali Taiel, MD
Vice President of Clinical Development, Gensight
GS010, a Novel Gene Therapy for Leber Hereditary Optic Neuropathy
15:29-15:34 Pete Adamson
Vice President, Head, Retinal Disease Area Stronghold, Janssen
Establishing Janssen’s Newest Leadership Area: Retinal Gene Therapy
15:35-15:42 Discussion

Session IV

MODERATORS: Eugene de Juan, MD and Kourous A. Rezaei, MD
15:43-15:48 Scott Dorfman
Chief Executive Officer, Odylia Therapeutics
Utilizing A Non-Profit Business Model for Ultra-Rare Indications
15:49-15:54 Christine Placet
Chief Executive Officer, Horama
Horama Pipeline Update
15:55-16:00 Christopher Brittain
Global Head of Ophthalmology Clinical Development, Genentech, Division of Roche Holding
Roche Gene Therapy Update
16:01-16:06 Benjamin Yerxa, PhD
Chief Executive Officer, Foundation Fighting Blindness
Role of FFB in Advancing Gene Therapy for Orphan Retinal Diseases
16:07-16:12 Mark Vezina
Scientific Director, Ocular and Neuroscience, Charles River Laboratories
Animal Models in Gene Therapy
16:13-16:18 Deborah Wild
Chief of Staff and VP of Corporate Development, Catalent Biologics, Paragon Gene Therapy
Challenges in Gene Therapy Manufacturing
16:19-16:26 Discussion
16:27-16:29 Kourous A. Rezaei, MD Final Remarks
16:30-17:00 Networking

Venue

Hotel Nikko, Nikko Ballroom
222 Mason Street, San Francisco, California
Register Now